As France's leading biocluster, Genopole is an incubator for cutting-edge projects in biotechnology. Located in the city of Évry, just south of Paris, Genopole provides a unique environment for scientists and entrepreneurs seeking to advance research and innovation.

Discover >


Genopole accompanies researchers, postdocs and start-up entrepreneurs through all the phases of their projects to ensure the best possible conditions for business development.

Discover >

Genopole’s citizens

Every day, at Genopole, researchers, entrepreneurs and students cross paths, share ideas and unite forces in a veritable melting pot for innovation.

Discover >


Giving wings to research and empowering employment in our community are cornerstones of Genopole's mission. Catch up on recent scientific advances, the accomplishments of our biotech actors and the events that enliven the biocluster.

Discover >

Innovate with us

Discover >


Pépinière Genopole Entreprises
4, rue Pierre Fontaine – Genopole Campus 3
91058 EVRY Cedex – FRANCE
Phone: +33 1 69 15 68 04

Frédéric CAROFF: President
Web Site >
LPS Biosciences - Genopole's company LPS Biosciences - Genopole's company

#Health / Well-being #R&D Services and Products

  • Endotoxin
  • Lipopolysaccharide (LPS)
  • Antigen
  • Structure
  • Extraction
  • Removal
  • Adjuvant
  • Vaccine

Field of Activity

– Bacterial endotoxin production, analysis and removal.
– Human and animal vaccines: R&D in antigens and adjuvants.
– Diagnostics: Antigen selection and production.
– Therapeutic Production: Endotoxin assay and removal for antibody production, hyaluronic acid or other production.
– Food Industry: Detection of bacterial pathogens.

LPS-BioSciences is specialized in bacterial endotoxins. It combines an exclusive proprietary technology for endotoxin production and characterization with the acknowledged international expertise of its founder Martine Caroff, D. Sc. (Director of Research at CNRS). The company received grants and support from OSEO and the Ministry of Research in 2011 for its innovative R&D project on a vaccine adjuvant.

The success of the company is now based on the know-how of its researchers in structural analysis (MALDI MS, RMN) and its acquired experience in the fields of vaccines, diagnostics, and the food industry.
Expert in Endotoxins Technology, LPS-BioSciences provides services, products and research, in the field of endotoxins, to companies active in human and animal health, cosmetics, agricultures and the food industry.

Our goal is to offer a consistent range of services and developments to meet the needs of our clients as concerns in endotoxins.

Fast-LPS: A range of services designed for industrials and academics who need purified LPS from specific bacteria. The development of exclusive LPS extraction methods without phenol enables the production of ultra purified endotoxins ready for antibody development and biological activity testing.

Target-LPS: Targe-LPS is a range of services designed for vaccine and diagnostics companies looking to select the best antigen for their product development. Our expertise in the relationship between structures and activities enables bacterial strain screening and validation for diagnostic and vaccine development.

Remov-LPS: A new range of services designed for industrial companies looking to remove endotoxins from therapeutic products. RemovShell enables the respect of the FDA’s pyrogen and endotoxins testing regulatory obligations.

Boost-LPS: LPS-BioSciences runs an innovative R&D program in the LPS-vaccine domain. The adjuvant capacity of detoxified lipid A molecules is well known and approved by the FDA to boost vaccine efficiency. Our research goal is to go further and provide a whole detoxified molecule of LPS with more adjuvant effect.

  • 2015: Proof of concept of Remov-LPS on industrial batches of hyaluronic acid.
  • 2015:3rd year of collaboration with CEVA animal health.
  • 2014: Partner of the collaborative R&D project BactiDIAG led by BioRad with the CEA Leti and the University Hospital from Nice in the sepsis diagnostic field.
  • 2013: Participation as supplier in the Infect ERA European program.
  • 2012: Prize winner in the Scientipôle cluster competition.
  • 2011: Prize winner in the French national business plan competition for high-tech start-ups.

Industrial partnerships:

  •  Co-development for vaccines, adjuvants.
  • Co-development for diagnostic tests (Gram negative pathogens).
  • Sub-licensing from LPS extraction patent.
  • Further Information

    1 patent (exclusive license agreement).
    staff members
    – On-demand, large-scale and highly purified LPS production.
    – Acknowledged expertise for LPS characterization, analytical device, innovative methods.
    Innovation assets:
    – Methods for endotoxin extraction and purification (without use of toxic solvents).
    – Methods for LPS assay to analyze complex samples.
    – Methods for LPS detoxification.

    Other facts: development of a vaccine adjuvant, based on an innovative endotoxin detoxification technology.

Genopole’s Companies

#R&D Services and Products

In same field

Quibiotic - Projet Shaker


Quibiotic develops three molecular synthesis platforms aimed at innovatively modifying β-lactam rings for new anti-infectives.

Adlin Science - Genopole's Company

Adlin Science

ADLIN Science accompanies researchers in the management, analysis and valorization of multiomic data

Altar - entreprise génopolitaine


Altar is a specialist in the conception and operation of automated fluidic continuous culture systems for adaptive laboratory evolution and the development of microbial strains for industry.

Yubsis - Genopole's company


Yubsis provides Biological Science Information Solutions. Our platform is designed for research organizations (Pharma, Biotech, academic lab) willing to improve real-time teamwork, optimize performance and accelerate innovation.

Xentech - Genopole Company


XenTech is an innovative biotech company specialized in the preclinical evaluation of cancer drugs and the identification of biomarkers and therapeutic targets.

Whitelab Genomics - Genopole's Company

WhiteLab Genomics

Artificial intelligence to optimize and accelerate the development of gene therapies

Pymabs - Genopole's Company


R & D services in the field of transient expression of recombinant proteins in plants.

Polytheragene - Genopole's Company


Manufacture and sale of new high performance transfecting agents for gene therapy, high-throughput screening and biomanufacturing. Cosmetic and therapeutic molecules from plant biomass.

Phinc Development - Genopole's Company

PhinC Development

PhinC Development brings its expertise to small and mid-sized biotechs and pharmaceutical companies looking to advance their early-stage drug research.

New England Biolabs - Genopole's Company

New England Biolabs France

New England Biolabs is a private company manufacturing reagents for the life science industry particularly focused on products for genomic research.

Hybrigenics - Genopole's company

Hybrigenics Services

Hybrigenics Services proposes fee-for-services R&D support and provides innovative technological platforms for i) protein interaction studies (protein-protein, drug-protein, mechanisms of action) and ii) selection and validation of VHH antibodies.

logo abcell Bio - Genopole's Companie


Abcell-bio is a laboratory specializing in the isolation of human hematopoietic stem cells and primary cells derived from perinatal tissue and cord blood.

View all >
With the support from